Prognosis of Adjuvant SOX vs XELOX Chemotherapy for Gastric Cancer After D2 Gastrectomy in Chinese Patients.

Shan YuYan WangXi ChengMinzhi LvYuehong CuiWei LiYiyi YuQian LiTian-Shu Liu

Published in: Cancer management and research (2020)

The results suggested that adjuvant SOX chemotherapy has similar survival benefits compared to XELOX chemotherapy in Chinese patients with pathological stage II or III GC after D2 gastrectomy.

Keyphrases

locally advanced
early stage
transcription factor
stem cells